Figure 3. Timing and frequency of predicted drivers in primary and metastatic breast cancers.

(A) DawnRank drivers from somatic mutations. (B) DawnRank copy number amplifications in at least 12 of 16 patients, and (C) deletions in at least 10 of 16 patients. Each alteration is characterized per patient as a founder alteration (gray), an alteration shared in the primary tumor and metastases (primary/mets) (purple), an alteration shared in 2 metastases but not in the primary tumor (pink), or an alteration private to 1 metastasis (blue). Copy number–altered drivers are annotated with the chromosomal cytoband location.